Cul3-KLHL20 ubiquitin ligase: physiological functions, stress responses, and disease implications by Hsin-Yi Chen et al.
Chen et al. Cell Div  (2016) 11:5 
DOI 10.1186/s13008-016-0017-2
REVIEW
Cul3-KLHL20 ubiquitin ligase: 
physiological functions, stress responses, 
and disease implications
Hsin‑Yi Chen1, Chin‑Chih Liu2,3 and Ruey‑Hwa Chen2,3*
Abstract 
Cullin‑RING ubiquitin ligases are the largest Ubiquitin ligase family in eukaryotes and are multi‑protein complexes. In 
these complexes, the Cullin protein serves as a scaffold to connect two functional modules of the ligases, the catalytic 
subunit and substrate‑binding subunit. KLHL20 is a substrate‑binding subunit of Cullin3 (Cul3) ubiquitin ligase. Recent 
studies have identified a number of substrates of KLHL20‑based ubiquitin ligase. Through ubiquitination of these 
substrates, KLHL20 elicits diverse cellular functions, some of which are associated with human diseases. Furthermore, 
the functions, subcellular localizations, and expression of KLHL20 are regulated by several physiological and stressed 
signals, which allow KLHL20 to preferentially act on certain substrates to response to these signals. Here, we provide 
a summary of the functions and regulations of KLHL20 in several physiological processes and stress responses and its 
disease implications.
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Background
Protein ubiquitination regulates a broad range of physi-
ological processes and disease conditions. Originally 
identified as a mechanism that targets protein for deg-
radation by the 26S proteasome [1, 2], ubiquitination is 
now appreciated as the most versatile posttranslational 
modification given the ability to conjugate structurally 
and functionally distinct ubiquitin polymer to the sub-
strate [3]. A critical step in the protein ubiquitination 
involves ubiquitin ligase, which transfers the ubiquitin 
moiety to the substrate to confer substrate specificity 
[4]. Cullin-RING multi-protein complexes comprise the 
largest family of ubiquitin ligases, in which one particu-
lar Cullin serves as a scaffold for linking two functional 
modules: the catalytic RING finger protein Rbx1 or Roc2 
and the substrate-binding module for bringing substrate 
within the proximity to the catalytic module [5]. In the 
Cullin3 (Cul3) family of ubiquitin ligases, the Bric-a-brac/
tramtrack/broad complex (BTB) domain-containing pro-
tein functions as the substrate adaptor to bridge Cul3 and 
substrate, which is in analogous to the Skp1-F-box heter-
odimer in the Cullin1 complex [6, 7]. The human genome 
contains nearly 200 BTB proteins [8], suggesting the 
existence of large numbers of distinct Cul3 complexes.
The BTB domain, also known as BTB/POZ domain, 
was originally identified as a protein–protein interaction 
domain [9]. Most BTB family proteins contain one or two 
other domains and therefore can be classified into sev-
eral subfamilies. Among them, the kelch-repeat domain 
subfamily is most prevalent in metazoan [8]. The human 
genome contains more than 50 BTB-kelch members, 
which are termed as Kelch-like 1-42 (KLHL1-42) and 
kelch and BTB domain containing 1-14 (KBTBD1-14) 
with the KLHL proteins containing an additional BACK 
domain in between the BTB and kelch domain [10, 11]. 
In BTB-kelch proteins, the BTB domain adopts a five 
α-helical fold resembling other Cullin-binding proteins 
in the Cullin-RING ligase complexes, such as Skp1 and 
ElonginC [8]. In addition, a 3-box motif in the proximal 
part of BACK domain (also known as IVR domain) also 
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contributes to the interaction with Cul3 [10, 12]. This 
explains why certain BTB-domain proteins lacking the 
3-box region, such as BTBD12, are not co-purified with 
Cul3 from cells [12]. The most C-terminus of these pro-
teins contains the kelch-repeat domain which forms a 
β-propeller structure for substrate interaction [13].
To date, many Cul3 substrate adaptors have been dis-
covered and their ubiquitination plays pivotal roles in 
various cellular processes and disease states (Fig. 1). For 
instance, the prototype of BTB-kelch protein Keap1 (des-
ignated as KLHL19) mediates the ubiquitin-dependent 
degradation of Nrf2, a master regulator of anti-oxidant 
responses [14, 15]. KLHL3, another BTB-kelch protein, 
targets WNK kinases for degradation which is important 
for blood pressure homeostasis [16, 17]. SPOP, a BTB/
POZ-containing protein, plays context-dependent roles 
in tumorigenesis, i.e., suppressing prostate cancer by 
inducing the destruction of androgen receptor and ERG 
oncoprotein and promoting kidney cancers through the 
degradation of tumor suppressor proteins PTEN, ERK 
phosphatases, Daxx, and Gli2 [18–21]. KLHL20 was dis-
covered before the identification of a functional link of 
BTB-kelch proteins to Cul3 ubiquitin ligases. This 64-kDa 
protein was discovered by its recruitment to the adherent 
junction of epithelial cells, implicating an involvement in 
cell–cell adhesion [22]. Furthermore, KLHL20 is induced 
by Wnt inhibitor DKK1 in keratinocytes and in the Mel-
anoDerm of skin [23]. Subsequent studies indicated that 
KLHL20 forms a ubiquitin ligase complex with Cul3 and 
Rbx1 [24]. To date, a number of substrates of this com-
plex have been identified, which collectively point to its 
versatile functions. This review will provide an overview 
of the functions of KLHL20 in several cellular processes 
and disease states and its regulation under various physi-
ological and stressed conditions (Fig. 2). Finally, we will 
highlight a number of key questions that remain to be 
answered.
Regulation of cell death
The first substrate identified for Cul3-KLHL20 ubiquitin 
ligase is death-associated protein kinase (DAPK). Origi-
nally discovered as a mediator of interferon-γ (IFN-γ)-
induced cell death [25], DAPK is subsequently found to 
function as a positive regulator of apoptosis in response 
to a wide range of stimuli, such as TNF-α, Fas [26], 
TGF-β [27], ceramide [28], oncogene activation [29], 
unligated netrin receptor [30, 31], matrix detachment 
[32], ER stress [33], and neurotoxicity [34], and can also 
regulate autophagic cell death and programmed necro-
sis [35–37]. In addition to promoting cell death, DAPK 
elicits other anti-cancer functions, such as suppression 
of metastasis by regulating cell migration, adhesion, and 
cytoskeleton remodeling [32, 38–40] and inhibition of 
cell transformation by inactivating the phospho-Ser/Thr 
directed isomerase Pin1 [41]. In line with these tumor 
suppressive functions, DAPK expression or activity is 
Fig. 1 Overview of certain important targets and functions of Cul3 ubiquitin ligases
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frequently downregulated in various types of human 
cancers through hypermethylation- or miRNA-induced 
gene silencing or posttranslational modification-induced 
inactivation [42–45]. The linkage of DAPK to KLHL20 
was first identified through a yeast two-hybrid screen in 
which the death domain of DAPK is capable of binding a 
C-terminal portion of KLHL20. Further analysis revealed 
that KLHL20 interacts with DAPK in mammalian cells 
under physiological conditions. Furthermore, KLHL20 
utilizes its kelch-repeat domain to recruit DAPK to Cul3. 
The Cul3-KLHL20 ubiquitin ligase promotes DAPK pol-
yubiquitination and proteasomal degradation. Through 
such a mechanism, KLHL20 elicits an anti-apoptotic 
function by counteracting DAPK-induced apoptosis [24].
Interestingly, the Cul3-KLHL20-mediated DAPK 
ubiquitination and degradation is blocked in response 
to IFN-α or IFN-γ treatment, which provides an expla-
nation for an important role of DAPK in apoptotic and 
autophagic death induced by these stimuli. Mechanis-
tically, this regulation of DAPK ubiquitination is attrib-
uted to a subcellular redistribution of KLHL20. Under 
IFN-α/γ-treated conditions, KLHL20 is enriched in a 
nuclear subdomain called PML-nuclear body, thereby 
separating KLHL20 from the cytoplasm/actin cytoskel-
eton-localized DAPK. The redistribution of KLHL20 to 
PML-nuclear bodies is presumably triggered by IFN-α/γ-
induced transcription of PML [46, 47], as PML competes 
with DAPK for binding KLHL20 [24]. In support of this 
notion, in certain multiple myeloma cells where IFN-α/γ 
fail to induce PML and PML-nuclear bodies, KLHL20 
retains in the cytoplasm and perinuclear region, thus 
allowing a persistent ubiquitination and degradation of 
DAPK. Importantly, such persistent DAPK destabiliza-
tion accounts for one mechanism by which tumor cells 
are resistant to IFN-α/γ treatment [24]. Thus, KLHL20 
is capable of controlling the effectiveness of IFN-based 
anti-cancer therapy through destabilizing the pro-death 
factor DAPK.
Suppression of PML tumor suppressive functions
The findings of a localization of KLHL20 in PML-nuclear 
bodies and its interaction with PML under IFN-α/γ-
treated conditions imply a link of KLHL20 to PML. The 
PML (promyelocytic leukemia) gene was originally iden-
tified based on its localization at the break point of the 
t(15:17) chromosome translocation found in most cases 
of acute promyelocytic leukemia [48]. The PML pro-
tein is essential for the formation of PML-nuclear bod-
ies [49] and elicits pleiotropic anti-tumor effects, such 
as suppression of proliferation, neoangiogenesis, cell 
migration, and promotion of apoptosis and senescence 
[50–53]. Additionally, PML regulates cancer cell metab-
olism and suppresses cancer stem cell maintenance [54, 
55]. Consistent with these tumor suppressive functions, 
the expression of PML protein, but not its mRNA, is 
frequently lost or reduced in a wide range of human 
malignancies, such as colon, lung, prostate, breast, brain 
tumors, germ cell tumors, and non-Hodgkin’s lymphoma 
[56]. Evidence has emerged that ubiquitin-mediated pro-
teasomal degradation is a key mechanism for PML deg-
radation in tumors [57]. The Cul3-KLHL20 complex has 
been demonstrated to mediate PML polyubiquitination, 
leading to the downregulation of PML protein and PML-
nuclear bodies [58]. However, targeting PML to KLHL20 
Fig. 2 Overview of the regulators, effectors and biological functions of KLHL20
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requires two consecutive posttranslational modifications 
on PML, that is, phosphorylation at S518 by CDK1/2 fol-
lowed by Pin1-mediated prolylisomerization of the pep-
tide bond between S518 and P519. This finding indicates 
a cell cycle-dependent regulation of PML stability, which 
is consistent with the highest PML protein level in the G1 
phase [59]. Since CDK1/2 activity and Pin1 expression 
are frequently upregulated in tumors, KLHL20-depend-
ent PML ubiquitination and degradation is expected to be 
enhanced in tumors. Furthermore, KLHL20 is expected 
to elicit certain oncogenic roles through blocking the 
tumor suppressive effects of PML. Indeed, KLHL20 con-
fers tumor-promoting functions, such as transformation, 
migration, and survival, which are dependent on PML 
downregulation [58].
Participation in tumor hypoxia responses 
and angiogenesis
An additional layer of the regulation of KLHL20-medi-
ated PML ubiquitination comes from the identification of 
KLHL20 as a transcriptional target of hypoxia-inducible 
factor-1 (HIF-1) [58]. HIF-1 and its paralog HIF-2 are key 
molecules to mediate the adaptation of hypoxia by tran-
scriptional activation of a large panel of genes containing 
“hypoxia responsive element” (HRE) on their promot-
ers [60]. The promoter of KLHL20 contains two HREs 
which are both involved in hypoxia-induced transactiva-
tion. Consistent with the induction of KLHL20 by HIF-
1, ubiquitination and degradation of PML is potentiated 
in hypoxia conditions through a HIF-1- and KLHL20-
dependent manner [58]. Reciprocally, PML negatively 
regulates the translation of HIF-1α through a mecha-
nism involving mTOR deactivation [50]. The counter-
inhibitory circuit between PML and HIF-1 indicates that 
KLHL20-mediated PML ubiquitination and degradation 
participates in a double- negative feedback regulation 
to potentiate HIF-1α accumulation in hypoxia condi-
tions. In support of this hypothesis, KLHL20 knockdown 
significantly attenuates hypoxia-induced HIF-1α and 
HIF-2α [58]. Thus, the KLHL20/PML pathway not only 
downregulates tumor suppressor PML but also is part 
of a feedback control mechanism for a robust induction 
of HIF-1 and HIF-2 in response to hypoxia. HIF-1- and 
HIF-2-regulated transcriptional networks play a crucial 
role in many aspects of tumor biology, such as immor-
talization, autocrine growth, metabolic reprogramming, 
cancer stem cell maintenance, invasion, metastasis, 
tumor angiogenesis, and resistance to therapy [61]. These 
effects collectively contribute to the aggressiveness of dis-
eases and are termed as tumor hypoxia responses.
Importantly, KLHL20 is demonstrated to act as a 
positive regulator of various tumor hypoxia responses 
through PML degradation. Consistent with these 
tumor-promoting functions, aberrant expression of 
several key molecules of the KLHL20/PML pathway, 
such as HIF-1α [62], Pin1 [63], and PML [56], has been 
reported in many types of cancers. In human prostate 
cancer, high expression of HIF-1α, KLHL20, and Pin1 is 
frequent observed and correlates with PML low expres-
sion [58]. More importantly, patients displaying the sig-
nature of high HIF-1α, high KLHL20, high Pin1, and low 
PML expression pattern are found to be progressively 
increased with disease progression. These clinical find-
ings support the significance of KLHL20/PML pathway 
in the progression of prostate cancer and suggest a prom-
ise for targeting this pathway in the treatment of aggres-
sive prostate cancers.
In addition to regulating HIF-1α and HIF-2α indirectly 
through PML degradation, KLHL20 can also bind HIF-2α 
[64]. This study also showed a positive role of KLHL20 
in regulating HIF-2α protein expression and HIF-2α-
mediated gene expression through a hypoxia- and 
VHL-independent mechanisms, even though it remains 
undetermined whether KLHL20-HIF-2α interaction con-
tributes to these effects.
The important role of KLHL20 in hypoxia signaling is 
not confined to tumor cells. Indeed, KLHL20 is prefer-
entially expressed in endothelial cells where it is induced 
by hypoxia. Depletion of KLHL20 in endothelial cells 
impairs VEGF- and FGF-induced migration and sprout-
ing angiogenesis without affecting cell proliferation 
[65]. Mechanistic studies indicated that KLHL20 binds 
to RhoGEF ECT2 to control VEGF-induced RhoA acti-
vation. Taken together, KLHL20 can not only amplify 
tumor hypoxia responses to stimulate angiogenesis in 
tumor microenvironments but also function directly in 
endothelial cells to promote their migration and sprout-
ing angiogenesis.
Regulation of actin cytoskeletons and vesicular 
trafficking
The nomenclature of kelch domain was originated from 
Drosophila kelch, whose mutation results in a disorgan-
ized F-actin structure in the ring canals which connect 
oocyte with accessory cells [66]. Similar to kelch, many 
kelch domain proteins are known to bind and regulate 
actin cytoskeletons through their kelch domain [66]. 
KLHL20 is also able to bind F-actin in  vitro and colo-
calizes with F-actin at cell–cell contact sites in  vivo 
[22]. Although it remains unclear whether KLHL20 acts 
directly on actin cytoskeleton to modulate its architec-
ture and dynamics, a recent study indicates that KLHL20 
promotes the assembly of a particular pool of F-actin by 
catalyzing the ubiquitination of an actin-binding pro-
tein [67]. This study was initiated by the observation of 
a predominant localization of KLHL20 in a perinuclear 
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region coincident with the markers of Golgi appara-
tus, especially with the marker of Trans-Golgi network 
(TGN). Remarkably, the TGN distribution of KLHL20 
is disrupted by brefeldin A, which blocks the activation 
of Arf- or Arl-family GTPases. The Arf/Arl-depend-
ent recruitment of KLHL20 to TGN implies a role of 
KLHL20 in Golgi-mediated intracellular trafficking. 
Indeed, KLHL20 is essential for the anterograde trans-
port of several cargoes from TGN to plasma membrane 
or endosomes but is dispensable for retrograde transport. 
This function of KLHL20 is mediated by its involvement 
in the formation and elongation of post-Golgi carrier 
tubules [67], which are subsequently cleaved to generate 
transport vesicles [68].
Because the function of KLHL20 in anterograde 
transport is dependent on its interaction with Cul3, 
ubiquitination of a Cul3-KLHL20 substrate should be 
responsible for this trafficking function. Among the 
KLHL20-interacting proteins, coronin 7 (Crn7) is also 
involved in post-Golgi trafficking and functions in a 
step similar to KLHL20 in this process [69]. Biochemi-
cal analyses indicated that Crn7 is a bona fide substrate 
of Cul3-KLHL20 ubiquitin ligase [67]. However, unlike 
other substrates of this ubiquitin ligase, KLHL20 cannot 
influence on the stability of Crn7 but promotes an atypi-
cal K33-linked polyubiquitination on Crn7. This ubiq-
uitination facilitates the recruitment of Crn7 to TGN 
by binding to a ubiquitin-binding protein Eps15, which 
is translocated to TGN prior to Crn7 during post-Golgi 
trafficking. How would TGN recruitment of Crn7 con-
tribute to trafficking? Crn7 is an F-actin-binding protein 
and can stabilize F-actin filaments [70]. Short F-actin fila-
ments are assembled around Golgi apparatus where they 
are critical for the biogenesis of post-Golgi carriers [68, 
71, 72]. Indeed, the polymerization of F-actin, in con-
junction with myosin motors, exerts mechanical force to 
assist membrane deformation, leading to the formation 
of tubule carriers. Accordingly, blockage of K33-ubiqui-
tin chain formation, Crn7 ubiquitination, or Crn7-Eps15 
interaction each impairs the assembly of TGN-pool 
F-actin [67]. Conversely, enforced targeting of Crn7 to 
TGN bypasses the requirement of its K33-linked ubiqui-
tination for TGN-pool F-actin assembly and anterograde 
trafficking. Thus, KLHL20 controls post-Golgi transport 
by mediating a K33-polyubiquitination on the actin-reg-
ulating protein Crn7.
Regulation of neural morphogenesis
The influence of KLHL20 on cytoskeletons is not con-
fined to its action on Crn7. The Rho-family GTPase 
RhoA activates multiple effectors to control the dynam-
ics of actin and microtubules and RhoA activity is 
positively regulated by a family of guanine nucleotide 
exchange factors (RhoGFEs) [73]. The connection of 
KLHL20 to RhoGEF was discovered by studying its func-
tion in primary neurons. In both hippocampal and cor-
tical neurons, KLHL20 promotes neurite outgrowth and 
arborization and these effects require its interaction 
with Cul3 [74]. Subsequent analysis identified the brain-
enriched PDZ-RhoGEF as an interactor of KLHL20 and 
a substrate of Cul3-KLHL20 ubiquitin ligase. KLHL20-
mediated ubiquitination of PDZ-RhoGEF leads to its 
proteasomal degradation and consequently the inactiva-
tion of RhoA. Restriction of RhoA activity in turn facili-
tates the spreading of axonal growth cone and promotes 
neurite outgrowth. Importantly, the inhibitory effect of 
KLHL20 depletion in neurite outgrowth is rescued by 
depletion of PDZ-RhoGEF, indicating the critical func-
tion of KLHL20/PDZ-RhoGEF axis in regulating neural 
morphogenesis during differentiation.
Neurite outgrowth and arborization are crucial for 
the establishment of connections during the develop-
ment and remodeling of nervous system. Neurotrophins 
regulate a number of important functions in vertebrate 
nervous system including survival, differentiation, axon 
outgrowth, and myelination [75]. The physiological sig-
nificance of KLHL20/PDZ-RhoGEF axis is evidenced 
by its involvement in neurotrophin-induced neurite 
outgrowth [74]. It turns out that a p38 MAPK-induced 
phosphorylation on PDZ-RhoGEF is required for its 
recruitment to KLHL20. Neurotrophins, such as neuro-
trophin-3 and brain-derived neurotrophic factor, induce 
the activation of p38 MAPK [76], thereby resulting in a 
persistent degradation of PDZ-RhoGEF by KLHL20. In 
keeping with this mode of PDZ-RhoGEF regulation by 
neurotrophins, KLHL20 depletion or p38 inactivation 
blocks neurotrophin-induced neurite outgrowth. Fur-
thermore, depletion of PDZ-RhoGEF rescues the effect 
of p38 inhibitor on neurotrophin-induced neurite out-
growth. However, in the absence of p38 inhibitor, PDZ-
RhoGEF siRNA does not show any significant effect, 
consistent with its persistent degradation under this situ-
ation. Thus, stimulation of PDZ-RhoGEF degradation 
through KLHL20-dependent ubiquitination represents a 
mechanism for neurotrophin-induced neurite outgrowth, 
which indicates a key role of KLHL20/PDZ-RhoGEF axis 
in the morphogenesis of neural circuits.
Control of autophagy termination
The linkage between KLHL20 and autophagy was 
recently uncovered [77]. Autophagy is a lysosome-
dependent catabolic process which is critical for the 
maintenance of cellular homeostasis when cells encoun-
ter various stressed conditions. The autophagic process 
consists of several steps, in which ULK1 and VPS34 com-
plexes play essential roles in autophagy initiation and 
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autophagosome nucleation, respectively [78, 79]. ULK1 is 
a serine/threonine kinase and forms a functional complex 
with ATG13, FIP200, and ATG101. ULK1 is activated in 
response to autophagic stresses, such as starvation [80–
82]. The activated ULK1 in turn relays signals to VPS34 
complex, which comprises of the phosphatidylinositol 
3-kinase VPS34 and regulatory subunits VPS15, Bec-
lin-1, and ATG14 [83]. The activated VPS34 complex is 
recruited to phagophores, the sites of autophagosome 
formation, in an ULK1- and ATG14-dependent man-
ner [84, 85]. At phagophores, VPS34 generates PtdIns3P, 
which recruits other factors for autophagosome biogen-
esis [86, 87]. Autophagy is a dynamic and self-limiting 
process, which is gradually turned off after its activation 
[88].
The study unveiling a critical role of KLHL20 in 
autophagy termination was initiated by the identifica-
tion of ULK1 as an interacting protein of the kelch-repeat 
domain of KLHL20 [77]. Subsequent studies found that 
KLHL20-based Ubiquitin ligase promotes ULK1 ubiq-
uitination and proteasomal degradation. Notably, the 
interaction between KLHL20 and ULK1 is induced by 
starvation. Further biochemical analysis revealed that 
KLHL20 targets the Ser1042/Thr1046-autophospho-
rylated ULK1 for polyubiquitination. This mechanism 
constitutes a feedback regulation to specifically remove 
ULK1 that is activated by the autophagic process. In addi-
tion to ULK1, KLHL20 also controls autophagy-depend-
ent degradation of VPS34 and Beclin-1. This function is 
mediated by autophagy-induced recruitment of KLHL20 
to phagophores, where it colocalizes with Belcin-1 and 
VPS34 to facilitate their K48-linked ubiquitination. The 
degradation of ULK1, VPS34, and Beclin-1 further leads 
to the degradation of their complex components ATG13 
and ATG14. Collectively, KLHL20 coordinates the deg-
radation of multiple components of ULK1 and VPS34 
complexes through a direct or indirect mechanism. The 
continuous degradation of these autophagy-initiating 
factors gradually leads to their exhaustion in the pro-
longed phase of stressed conditions, and thus contrib-
utes to autophagy termination. Accordingly, depletion of 
KLHL20 or impairment of ULK1 autophosphorylation 
results in a persistent and excessive autophagy activity 
even at the prolonged starvation. Thus, KLHL20 func-
tions as a master regulator of autophagy termination.
What is the physiological significance of KLHL20-
mediated autophagy termination? At a cellular level, 
blockage of KLHL20-dependent autophagy regulation 
or impairment of ULK1 autophosphorylation increases 
cell death under prolonged starvation, indicating that 
autophagy termination prevents uncontrolled cellular 
degradation to maintain cell survival. At an organism 
level, skeletal muscle specific-KLHL20 knockout mice 
exhibit an aggravation of muscle atrophy in an experi-
mental diabetes model and this effect is dependent on 
excessive autophagy activity. Thus, KLHL20-dependent 
autophagy termination is important in maintaining tis-
sue homeostasis by preventing excessive muscle wasting 
under this disease state.
Lessons from KLHL20 knockout mice
Given the multiple functions of KLHL20, it is conceiv-
able that  >50  % of the KLHL20 knockout mice exhibit 
neonatal lethality [89, 90]. This neonatal death is associ-
ated with respiratory failure, reduced lung aeration, and 
increased septum thickness [90]. In addition, surfactant 
expression is significantly reduced, indicating a defect 
in the maturation of type II pneumocytes. Despite these 
defects, KLHL20 expression is absent in lung epithe-
lium but present in lung endothelial cells and pericytes. 
Furthermore, KLHL20−/− lung exhibit enhanced apop-
tosis and regressive vascularization. These findings sug-
gest that KLHL20 potentiates a paracrine function of 
lung endothelium to influence on the maturation of lung 
epithelium. Mechanistically, expression of HIF-2α and 
VEGF are significantly reduced in KLHL20 deficient 
lung. Given the importance of HIF-2α and VEGF in late-
stage maturation of type II pneumocytes [91–93], the 
KLHL20/HIF-2α axis likely underlines the lung develop-
ment defect seen in KLHL20−/− mice.
The KLHL20−/− mice that can survive beyond the neo-
natal stage show compensatory elevation of HIF-2α and 
VEGF expression for an unknown reason [90]. However, 
they display progressive corneal neovascular dystrophy 
starting as early as week 3 [89]. The pathology is initi-
ated by hyperplasia of the corneal epithelium, followed 
by conversion of non-keratinized corneal epithelium to 
superficially keratinized cells, and eventually leading to 
total corneal opacity. The abnormalities seen in the cor-
nea of KLHL20−/− mice are likely due to a decreased 
corneal epithelial integrity, consistent with the recruit-
ment of KLHL20 to the cell–cell adhesion sites seen in 
cultured epithelial cells [22]. During disease progression, 
massive corneal vascularization is also observed, which 
is associated with increased expression of angiopoietin-1 
and downregulation of miR-204, a negative regulator of 
angiopoietin-1 [94]. However, given the positive role of 
KLHL20 in angiogenesis in other systems, the corneal 
vascularization seen in KLHL20−/− mice is likely a sec-
ondary effect induced by high proliferation activity and 
scarification of the corneal epithelium.
The neonatal lethality of KLHL20−/− mice may hinder 
the analysis of its pathophysiological functions in the 
adulthood. This limitation is alleviated by the establish-
ment of KLHL20flox/flox mice which enable the study of 
KLHL20 function in a tissue-specific manner [77].
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Regulation of KLHL20
Regulation of KLHL20 subcellular distributions
The pleiotropic functions of KLHL20 are consistent with 
its diverse and variable subcellular localizations. In the 
normal culturing conditions, KLHL20 is predominantly 
distributed to a perinuclear region where it is colocal-
ized with markers of cis-Golgi, trans-Golgi, and TGN 
[67]. Quantitative analysis indicated that KLHL20 is most 
precisely colocalized with TGN marker. In addition to 
the perinuclear region, KLHL20 immunofluorescent sig-
nal is weakly detected in cytoplasm, nucleoplasm, PML-
nuclear bodies, and cell–cell contact region. As described 
above, KLHL20 subcellular localizations can be modu-
lated under several physiological settings and stressed 
conditions. In response to autophagy induction, KLHL20 
relocates to vesicle-like structures which partially overlap 
with the nascent phagophores marked by ATG16L [77]. 
Although ATG9 also travels from TGN to phagophore 
during autophagic process, KLHL20 vesicles do not 
overlap with ATG9 vesicles (Chin-Chih Liu and Ruey-
Hwa Chen, unpublished results). The nature of KLHL20 
vesicles and the mechanism of KLHL20 redistribution in 
response to autophagy are currently unknown.
Notably, even though KLHL20 is enriched in the Golgi 
apparatus, this distribution is not static and is dependent 
on the activity of Arf/Arl-family proteins [67]. This indi-
cates that Golgi-mediated intracellular trafficking facili-
tates a Golgi distribution of KLHL20. Likewise, KLHL20 
is transiently recruited to cell–cell junction during cell 
adhesion process through an E-cadherin- and F-actin-
dependent mechanism [22]. KLHL20 distribution to 
PML nuclear bodies is likely mediated by its interaction 
with PML, a key molecule for the assembly of this subnu-
clear domain. In response to signals that elevate the level 
of PML, such as IFN-α/γ, an enrichment of KLHL20 in 
PML-nuclear bodies is observed, which is accompanied 
with the decrease of its localization in cytoplasm [24]. 
Consequently, binding of KLHL20 to its cytoplasm sub-
strate is reduced. Thus, alteration of subcellular locali-
zation is likely a mechanism for KLHL20 to selectively 
target a particular set of substrates under specialized 
physiological conditions. This provides an opportunity 
for KLHL20 to participate in diverse cellular processes at 
a highly regulated basis.
Regulation of KLHL20 by KLHL39
In addition to regulating KLHL20 functions by altering 
its subcellular localizations, a recent study identified an 
inhibitory protein for KLHL20-based ubiquitin ligase. 
Interestingly, this inhibitor shares a similar domain struc-
ture with KLHL20 and is named KLHL39. Originally 
identified as a protein interacting with the NS1 protein 
of influenza A virus [95], KLHL39 was recovered from 
a yeast two-hybrid screen with the kelch-repeat domain 
of KLHL20 as bait [96]. Despite being recruited to the 
substrate-binding domain of KLHL20, KLHL39 is not a 
substrate of KLHL20-based Ubiquitin ligase. More sur-
prisingly, KLHL39 does not bind Cul3 by carrying cer-
tain nonconserved residues in regions of its BTB domain 
that are equivalent to regions critical for contacting Cul3 
in other BTB proteins. Subsequent analysis revealed 
that KLHL39 blocks KLHL20 binding to its substrates, 
such as DAPK and PML, implying that KLHL39 func-
tions as a pseudosubstrate for KLHL20-based ubiquitin 
ligase. However, unlike several pseudosubstrates for the 
Cul3-Keap1 ligase, KLHL39 can additionally disrupt the 
formation of KLHL20-Cul3 complex with an unknown 
mechanism. Through these dual inhibitory roles, i.e., 
inhibition of KLHL20 binding to Cul3 and substrates, 
KLHL39 blocks KLHL20-dependent ubiquitination and 
degradation of DAPK and PML, leading to an increase of 
their steady-state levels. These findings uncover not only 
a novel mode of regulatory mechanism for Cul3 family 
ligases but also a hierarchy among KLHL family mem-
bers. KLHL39 is likely evolved to divergent from the Cul3 
substrate adaptor role of KLHL family to an inhibitory 
role for a particular KLHL member, thus increasing the 
functional versatility of this family.
Since DAPK and PML both act as tumor suppres-
sors, the ability of KLHL39 to prevent their degradation 
predicts a similar function of KLHL39. In line with this 
notion, the murine ortholog of KLHL39, Nd1-L, is down-
regulated in metastatic lesions of colon cancers compared 
with the primary tumors and Nd1-L overexpression in a 
murine colon cancer cell line suppresses migration, inva-
sion, and metastasis [97]. Similar tumor suppressive 
functions are observed with KLHL39 in human colon 
cancer cell lines, and more importantly, these functions 
are all mediated by a PML- and DAPK-dependent man-
ner [96]. Clinical analysis revealed that low expression 
levels of KLHL39, DAPK, and PML are associated with 
metastatic progression of human colon cancers. These 
findings indicate a role of KLHL39-mediated PML and 
DAPK stabilization in colon cancer metastasis and imply 
an importance of KLHL20/KLHL39 ratio in determining 
the metastatic fate of tumor cells.
Conclusion remarks
In this review, we summarize the diverse functions of 
KLHL20 and most of these functions are mediated by 
ubiquitination of a particular protein. We also discuss 
several regulatory mechanisms for KLHL20-based ubiq-
uitin ligase, including the alterations of its expression 
and subcellular localizations, and the existence of an 
inhibitory protein. In addition to participating in many 
normal cellular processes, KLHL20 is regulated and 
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elicits important roles in several stressed conditions, 
such as hypoxia and autophagy. Furthermore, KLHL20 
is upregulated in certain tumors and possesses pleio-
tropic tumor-promoting functions through potentiat-
ing the degradation of tumor suppressor proteins DAPK 
and PML. KLHL20-based ubiquitin ligase is therefore a 
potential target of anti-cancer therapy.
Several important issues remain to be addressed. First, 
among the various KLHL20 substrates, it is unclear 
whether they carry a similar sequence motif, i.e., degron, 
for KLHL20 binding. Identification of KLHL20-specific 
degron would aid in the discovery of additional KLHL20 
substrates. Second, KLHL20 is capable of catalyzing pol-
yubiquitination with distinct chain specificities on dif-
ferent substrates, such as K33-linked chain on Crn7 and 
K48-linked chain on other substrates, but its underlying 
mechanism remains elusive. Third, KLHL20 knockout 
mice show a number of prominent defects but the pre-
cise molecular mechanisms are poorly characterized. It is 
also unclear whether these defects are related to insuffi-
cient ubiquitination of certain proteins. Answers to these 
questions would be helpful for our understanding of the 
functions and mechanisms of this versatile protein.
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